Trial · NCT03314935
Adverse events2,960
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,960
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | 0 | 8 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | 1 | 6 | 1 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 | 0 | 14 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + Gemcitabine + Cisplatin | 0 | 7 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + Gemcitabine + Cisplatin | 0 | 4 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin | 2 | 46 | 2 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | 0 | 7 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel | 0 | 5 | 0 |
| other | Abdominal discomfort | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel | 2 | 52 | 2 |
| other | Abdominal discomfort | Gastrointestinal disorders | Total | 5 | 149 | 5 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | 0 | 8 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | 0 | 6 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 | 0 | 14 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + Gemcitabine + Cisplatin | 0 | 7 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + Gemcitabine + Cisplatin | 0 | 4 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + Gemcitabine + Cisplatin | 5 | 46 | 5 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | 1 | 7 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel | 0 | 5 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel | 8 | 52 | 11 |
| other | Abdominal distension | Gastrointestinal disorders | Total | 14 | 149 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03314935/events